Zyrik 300 Tablet contains Allopurinol 300 mg, a xanthine oxidase inhibitor primarily indicated for the management of hyperuricemia and gout. By inhibiting xanthine oxidase, Allopurinol reduces the production of uric acid, thereby preventing the formation of urate crystals that cause gouty arthritis and renal complications. Zyrik 300 is prescribed for the long-term treatment of chronic gout, prevention of uric acid nephropathy, and management of hyperuricemia associated with malignancies or chemotherapy. It is also utilized in the prevention of recurrent calcium oxalate calculi in patients with elevated uric acid levels. The tablet should be taken orally, preferably after meals to minimize gastrointestinal discomfort. Dosage must be individualized based on serum uric acid levels and renal function, with regular monitoring recommended to avoid adverse effects. Common side effects include rash, gastrointestinal disturbances, and hypersensitivity reactions; severe hypersensitivity syndrome, though rare, necessitates immediate discontinuation. Caution is advised in patients with renal or hepatic impairment. Zyrik 300 should not be used during acute gout attacks but rather as prophylaxis. Concomitant use with azathioprine or mercaptopurine requires dose adjustment due to potential drug interactions. Overall, Zyrik 300 Tablet is an effective therapeutic option for controlling hyperuricemia and preventing gout-related complications.